Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

1.

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

Medrano J, Neukam K, Rallón N, Rivero A, Resino S, Naggie S, Caruz A, Calvino A, Macías J, Benito JM, Sánchez-Piedra C, Vispo E, Barreiro P, McHutchison J, Pineda JA, Soriano V.

Clin Infect Dis. 2010 Nov 15;51(10):1209-16. doi: 10.1086/656811.

PMID:
20964522
[PubMed - indexed for MEDLINE]
Free Article
2.

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, Palomares JC, Mira JA, Martínez A, Roldán C, de la Torre J, Macías J.

Clin Infect Dis. 2010 Oct 1;51(7):788-95. doi: 10.1086/656235.

PMID:
20804372
[PubMed - indexed for MEDLINE]
Free Article
3.

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.

Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM.

AIDS. 2011 May 15;25(8):1025-33. doi: 10.1097/QAD.0b013e3283471cae.

PMID:
21505315
[PubMed - indexed for MEDLINE]
4.

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.

AIDS. 2008 Jan 2;22(1):15-21.

PMID:
18090387
[PubMed - indexed for MEDLINE]
5.

Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.

Soriano V, Núñez M, Camino N, Maida I, Barreiro P, Romero M, Martin-Carbonero L, Garcia-Samaniego J, González-Lahoz J.

Antivir Ther. 2004 Aug;9(4):505-9.

PMID:
15456081
[PubMed - indexed for MEDLINE]
6.

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.

Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K.

Gut. 2011 Feb;60(2):261-7. doi: 10.1136/gut.2010.223495. Epub 2010 Nov 10.

PMID:
21068134
[PubMed - indexed for MEDLINE]
7.

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.

J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19.

PMID:
21129805
[PubMed - indexed for MEDLINE]
8.

Degree of viral decline early in treatment predicts sustained virological response in HCV-HIV coinfected patients treated with peginterferon alfa-2a and ribavirin.

Rodriguez-Torres M, Torriani F, Rockstroh J, Depamphilis J, Carosi G, Dieterich DT.

HIV Clin Trials. 2010 Jan-Feb;11(1):1-10. doi: 10.1310/hct1101-1.

PMID:
20400406
[PubMed - indexed for MEDLINE]
9.

Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.

Mira JA, Valera-Bestard B, Arizcorreta-Yarza A, González-Serrano M, Torre-Cisneros J, Santos I, Vergara S, Gutiérrez-Valencia A, Girón-González JA, Macías J, López-Cortés LF, Pineda JA.

Antivir Ther. 2007;12(4):523-9.

PMID:
17668561
[PubMed - indexed for MEDLINE]
10.

Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.

Ladero JM, Martin EG, Fernández C, Carballo M, Devesa MJ, Martínez C, Suárez A, Díaz-Rubio M, Agúndez JA.

J Gastroenterol Hepatol. 2012 Feb;27(2):279-85. doi: 10.1111/j.1440-1746.2011.06834.x.

PMID:
21722179
[PubMed - indexed for MEDLINE]
11.

Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.

Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K.

J Gastroenterol Hepatol. 2012 Sep;27(9):1467-72. doi: 10.1111/j.1440-1746.2012.07129.x.

PMID:
22432893
[PubMed - indexed for MEDLINE]
12.

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.

Hepatology. 2010 Aug;52(2):421-9. doi: 10.1002/hep.23690.

PMID:
20648473
[PubMed - indexed for MEDLINE]
13.

Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.

Ramos B, Núñez M, Rendón A, Berdún MA, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Barreiro P, Romero M, Labarga P, Guardiola JM, Garcia-Samaniego J, Soriano V.

J Viral Hepat. 2007 Jun;14(6):387-91.

PMID:
17501758
[PubMed - indexed for MEDLINE]
14.

Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.

Núñez M, Mariño A, Miralles C, Berdún MA, Sola J, Hernandez-Burruezo JJ, Galindo MJ, Barreiro P, Martin-Carbonero L, Soriano V.

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):439-44. Erratum in: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):528. Mariño, Angel [corrected to Mariño, Ana].

PMID:
17468669
[PubMed - indexed for MEDLINE]
15.

Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.

Sanjo M, Saito T, Ishii R, Nishise Y, Haga H, Okumoto K, Ito J, Watanabe H, Saito K, Togashi H, Fukuda K, Imai Y, El-Shamy A, Deng L, Shoji I, Hotta H, Kawata S.

J Med Virol. 2010 Aug;82(8):1364-70. doi: 10.1002/jmv.21818.

PMID:
20572079
[PubMed - indexed for MEDLINE]
16.

Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection.

Morello J, Cuenca L, Soriano V, Medrano J, Madejón A, Vispo E, Barreiro P, Labarga P, Jiménez-Nácher I, Rodríguez-Nóvoa S.

J Infect Dis. 2010 Oct 15;202(8):1185-91. doi: 10.1086/656334.

PMID:
20812847
[PubMed - indexed for MEDLINE]
Free Article
17.

Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.

Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P; Italian Co-infection Study (ICOS) Group.

Antivir Ther. 2005;10(2):309-17.

PMID:
15865225
[PubMed - indexed for MEDLINE]
18.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

PMID:
15461877
[PubMed - indexed for MEDLINE]
Free Article
19.

Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.

Núnez M, Camino N, Ramos B, Berdún MA, Barreiro P, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Martín-Carbonero L, Romero M, García-Samaniego J, Soriano V.

Antivir Ther. 2005;10(5):657-62.

PMID:
16152759
[PubMed - indexed for MEDLINE]
20.

Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.

Núñez M, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de Los Santos I, San Joaquín I, Echeverría S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola JM, Romero M, García-Samaniego J, Soriano V; PRESCO Study Group.

AIDS Res Hum Retroviruses. 2007 Aug;23(8):972-82.

PMID:
17725413
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk